Aspire-Lakewood (ASBP) vs GT Biopharma (GTBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed Aspire-Lakewood (ASBP) over the past year, gaining 451.9% versus a loss of 43.0%. Aspire-Lakewood is the larger company by market cap ($11.7 million vs $11.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | GTBP |
|---|---|---|
| Share price | $8.32 | $6.24 |
| Market cap | $11.66M | $11.25M |
| 1-day change | +0.18% | +4.79% |
| YTD return | +57.20% | +659.24% |
| 1-year return | -42.99% | +451.85% |
| 5-year return | — | -96.72% |
| EPS (TTM) | $-30.89 | $-147.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.76 | $28.75 |
| 52-week low | $0.11 | $4.91 |
| Distance from 52-week high | -55.68% | -78.31% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1102.89% |
| Average volume | 37.15K | 55.52K |
| Shares outstanding | 1.40M | 1.80M |
| Employees | — | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed ASBP by 494.8 percentage points over the past year.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Health Care · Biotechnology: Pharmaceutical Preparations
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
ASBP vs GTBP FAQ
Which is bigger, Aspire-Lakewood or GT Biopharma?
Aspire-Lakewood (ASBP) is larger, with a market capitalization of $11.66M compared with $11.25M for GT Biopharma (GTBP).
Which stock has performed better over the past year, ASBP or GTBP?
GTBP returned +451.85% over the past 12 months, compared with -42.99% for ASBP (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and GT Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.